Stay updated on PLACARD Trial: CXD101 + Pembrolizumab in DLBCL
Sign up to get notified when there's something new on the PLACARD Trial: CXD101 + Pembrolizumab in DLBCL page.

Latest updates to the PLACARD Trial: CXD101 + Pembrolizumab in DLBCL page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedCore page content updated with a government operating status notice and a new resource topic; software revision updated from v3.1.0 to v3.2.0. No other significant changes.SummaryDifference3%
- Check18 days agoChange DetectedMajor change: version updated to v3.1.0 with removal of a specific disease resource (Diffuse large B-cell lymphoma) from the Genetics and Rare Diseases Information Center; no new substantive content added.SummaryDifference0.5%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedUpdated page revision from v3.0.1 to v3.0.2. Removed the Back to Top navigation element.SummaryDifference0.2%
- Check39 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%
- Check47 days agoChange DetectedThe web page has undergone significant changes, including the addition of new medical terms and disease classifications related to diffuse large B-cell lymphoma, while also removing several related terms and location details.SummaryDifference4%
- Check61 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to PLACARD Trial: CXD101 + Pembrolizumab in DLBCL
Enter your email address, and we'll notify you when there's something new on the PLACARD Trial: CXD101 + Pembrolizumab in DLBCL page.